Evogene Ltd.

Equities

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 08:49:38 2024-05-26 am EDT 5-day change 1st Jan Change
295.3 ILa +2.71% Intraday chart for Evogene Ltd. +17.88% -1.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M MT
Transcript : Evogene Ltd., Q1 2024 Earnings Call, May 23, 2024
Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd CI
Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq MT
Transcript : Evogene Ltd., Q4 2023 Earnings Call, Mar 07, 2024
Evogene Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Evogene Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules MT
AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides CI
Casterra Announces New Agreements with Subsidiary of Evogen Ltd., to Meet Growing Demand for Its Elite Castor Seed Varieties CI
Evogene Files $200 Million Mixed Shelf MT
Evogene Ltd. and Verb Biotics LLC Enters into Collaboration Agreement CI
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024 CI
Transcript : Evogene Ltd., Q3 2023 Earnings Call, Nov 15, 2023
Earnings Flash (EVGN) EVOGENE Posts Q3 Revenue $3.8M MT
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Colors Farm Ltd, Evogene Ltd. and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology CI
Alliance Global Starts Evogene at Buy With $1.85 Price Target MT
Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating MT
Transcript : Evogene Ltd., Q2 2023 Earnings Call, Aug 17, 2023
Earnings Flash (EVGN) EVOGENE Posts Q2 Revenue $654,000 MT
Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery CI
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program CI
Chart Evogene Ltd.
More charts
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. EVGN Stock
  4. News Evogene Ltd.
  5. Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules